Buy ENOVID Virx - SaNOtize Nitric Oxide Nasal Spray- Free Shipping

Free Delivery

WORLDWIDE EXPEDITED DELIVERY

Heading

Special Offer! 5-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

Special Offer! 5-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$220.00
2-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

2-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$105.00
3-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

3-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$145.00
4-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

4-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$185.00
Special Offer! 5-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

Special Offer! 5-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$220.00
2-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

2-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$105.00
3-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

3-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$145.00
4-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

4-PACK Enovid SaNOtize Nitric Oxide Nasal Spray (NONS)

$185.00

AS SEEN ON

AND OVER 350 NEWS SITES

Customer Reviews

Why Sanotize?

Already tested positive?
99% Reduction in COVID-19 Viral Load

Glenmark Phase III clinical trial shows reduction in SARS-CoV-2 log viral load by 94% within 24 hours, and by more than 99% in 48 hours.

Stay Safe Everywhere

Protect yourself from viruses at work or school, during meetings or when using public transportation and flights.

Use SaNOtize NONS Daily

Enovid can be used as a proactive measure or to reduce the viral load. It kills viruses in the nasal cavity, the main "gateway" to viruses in the respiratory tract and significantly reduces the viral load in the body. Easy to use and made from natural ingredients only.

PHASE 3 CLINICAL TRIAL CONFIRMS
SANOTIZE’S TREATMENT IS 99% EFFECTIVE
AGAINST COVID-19!

On Feb 9, 2022 SaNOtize announced the completion of Phase 3 trial in India for its nitric oxide nasal spray. The trial reached primary endpoint:

Reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours

The double-blind, parallel arm, multicenter study, conducted in 306 patients in non-hospitalized adult patients. NONS was safe and well tolerated by patients. No patients experienced moderate, severe, serious Adverse Events (AE) or death in the study.

BUY NOW

Videos About Enovid

DR. REGEV, CO-FOUNDER OF SANOTIZE, ON COVID-FIGHTING NASAL SPRAY

AN INTERVIEW WITH Dr. CHRIS MILLER, CO-FOUNDER OF SANOTIZE

A live interview by the Out of the Doldrums Youtube Channel

Enovid News

What Is Enovid, and How Does It Work? A Deep Dive into Its Science and Applications

On March 05, 2024 0 Comment

What is Enovid? Many people have heard of the medication, and it’s time to learn more about it.  Enovid contains nitric oxide (NO). Scientists fully understand NO and have studied the nano-molecule, which is found naturally in the body.  It features many physiologic functions, such as regulating a person’s immune system and dilating their blood vessels. Initially, Enovid was introduced for therapeutic approval in 1999 to treat blue baby syndrome, which is persistent pulmonary hypertension in newborns.  Scientists have studied nitric oxide for many decades, determining that it features strong antimicrobial properties against various pathogens. When you deliver NO to...

Read More

SaNotize Enovid Nasal Spray: A Powerful Defense Against COVID Variants, Flu, and Cold Viruses

On December 05, 2023 0 Comment

Introduction to SaNotize Enovid Nasal Spray In these challenging times of COVID-19, it has become more important than ever to protect our health and that of our loved ones from the threat of COVID variants, flu, and cold viruses. One powerful defense that has emerged is the SaNotize Enovid Nasal Spray, which you can buy online. This innovative enovid spray is designed to provide effective antiviral protection, bolstering our immune system against various respiratory viruses, including COVID variants, flu, and cold viruses. In this article, we will explore the science behind SaNotize Enovid Nasal Spray, its benefits, and how it...

Read More

Gilly Regev and Chris Miller write about The Power of Nitric Oxide on MedCityNews.com

On January 23, 2023 0 Comment

"The Power of NO: How a Tiny Natural Molecule Can Help Shift How We Treat Covid-19 and Other Infections While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally." Published on Jan 4th, 2023 on MedCityNews.com, By Gilly Regev and Chris Miller Click here to read the full article 

Read More

The Jerusalem Post: Can an anti-viral nasal spray stop Corona and other viruses?

On January 23, 2023 0 Comment

"Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in Israel, has been proven effective in preventing viruses – including COVID-19 – from entering the body through the nasal cavity."   Published: JANUARY 3, 2023 12:13 on the Jerusalem post, click to READ MORE

Read More

SaNOtize moves to carve a new market demand: over-the-counter prevention

On September 22, 2022 0 Comment

There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October.  It’s a deviation for the company that until now has been developing the nitric oxide nasal spray (NONS) as an early antiviral treatment, primarily assessing a reduction in viral load and testing time. But the takeaway from the company’s July 18 meeting with regulators was that those two markers wouldn’t be sufficient primary endpoints in a phase 3 treatment trial over a reduction...

Read More

SaNOtize raised $24M to fund phase 3 trial of COVID-19 nasal spray

On September 22, 2022 0 Comment

SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS).   The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in sprays, baths, lavages, gels and creams. Interest in the platform went up a gear in 2020 when COVID-19 created a pressing need for interventions capable of treating and preventing SARS-CoV-2 infection. Published by Nick Paul Taylor on Aug...

Read More

Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure

On May 31, 2022 0 Comment

Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001). The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure. The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate. The study was carried out during an...

Read More

Phase 3 Clinical Trial Confirms SaNOtize’s Treatment is 99% Effective Against COVID-19

On February 10, 2022 0 Comment

SaNOtize and Glenmark Pharmaceuticals Limited has announced on February 09, 2022: Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours Treatment also demonstrated, in the high-risk group (n=218), a greater proportion of patients who achieved a combination of clinical and virological cure, based on the WHO Progression Scale Median time to virological cure was 4 days in the treatment group, 8 days in the placebo group (p < 0.05). A Phase 3 clinical trial was...

Read More

Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company

On January 09, 2022 0 Comment

Amorphical, an Israeli biotech company developing Amorphous Calcium Carbonate (ACC) has announced results of a phase II clinical trial. Amorphical’s Novel COVID-19 Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Published by Amorphical, Ness Ziyona, Israel | January 06, 2022  https://newsdirect.com/news/outstanding-preliminary-results-of-a-clinical-trial-treating-moderate-to-severe-covid-19-patients-conducted-by-amorphical-an-israeli-biotechnology-company-973592489   Read more on the Jerusalem Post (published December 22, 2021): https://www.jpost.com/health-and-wellness/coronavirus/article-689543    

Read More

SaNOtize faces increased demand and is now seeking to raise funds to support production expansion

On November 13, 2021 0 Comment

SaNOtize reports that NONS sales in Q3 2021 were $5M and are projected to exceed $9M by the end of 2021. SaNOtize anticipates 2022 revenues will be $70-100M - the timing of approvals in various countries is a key driver of sales volume. With healthy contribution margins, the company believes it could be cash flow positive by the end of 2022. The company is now raising additional funds through OurCrowd platform;  To read more about this investment opportunity, here is a link to SaNOtize's company page.  

Read More

BNN Bloomberg: An Interview with Dr. Gilly Regev of SaNOtize

On November 13, 2021 0 Comment

U.K. clinical trials for Vancouver’s SaNOtize have confirmed that its nasal spray reduced SARS-CoV-2 log viral load by more than 95 per cent in infected participants within 24 hours of treatment, and by more than 99 per cent in 72 hours. While the product is set to sell over the counter in Israel and New Zealand pharmacies, Dr. Gilly Regev says Health Canada sees their product as a drug and not a medical device, hindering the ability for SaNOtize to be available to the Canadian market sooner rather than later.

Read More

Nitric Oxide Nasal Spray Reduces Covid-19 Viral Load By 95% Within 24 Hours: Study

On September 26, 2021 0 Comment

Tyler Durden is reviewing the recent results of SaNOtize clinical study in the UK, click here to read the article 

Read More

Could Protection from COVID Soon Be Available Through a Nasal Spray?

On September 26, 2021 0 Comment

Renée Reardin is writing about SaNOtize’s nasal spray and provide some useful information about clinical trails and the potential of enovid in fighting covid-19 Click here to read more at Best Health

Read More

SaNOtize commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

On September 26, 2021 0 Comment

SaNOtize inks agreement with Indian biotech Glenmark to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets Click here to read more at Businesswire.com

Read More

Where to buy SaNOtize nasal spray

On September 01, 2021 0 Comment

Enovid is approved by the Israeli MOH to be sold in pharmacies across Israel. The product which was developed by Canadian Bio company SaNOtize is manufactured in Israel. This website allows you to purchase enovid online. We ship worldwide with 3-5 days delivery by DHL. You can buy Enovid online and have SaNOtize NANOS nasal spray with you within days. Enovid is offered here at 2-PACK or 3-PACK. You can read more about Enovid at SaNOtize website: https://sanotize.com/enovid/ From the Press: Canadian Biotech Progresses COVID-19 Nasal Spray, Claims Promise Against Variants (published on scrip.pharmaintelligence.informa.com, 30 June, 21): The Vancouver, Canada-based biotech...

Read More